Literature DB >> 25005764

Chronic Venous Disease and Comorbidities.

P Matic1, S Jolic2, S Tanaskovic1, I Soldatovic3, N Katsiki4, E Isenovic5, Dj Radak1.   

Abstract

We report the relations between comorbidities and chronic venous disease. In this cross-sectional study, information was gathered from 1679 Serbian patients. The majority (65.0%) of patients were women. Mild forms of chronic venous disease (clinical, etiologic, anatomic and pathophysiologic [CEAP] classification; C0s-C1) were more frequent in women (11.6%), while severe forms (CEAP C4-C6) were more commonly encountered in men (42.1%). The most frequent comorbidity was emphysema/chronic obstructive pulmonary disease in both groups (74.3% in males and 70.6% in females). For females, diabetes mellitus (P < .005), arterial hypertension (P < .000), and skeletal/joint diseases (P < .042) were more commonly found in the C4 to C6 category. Both males and females, with severe form of chronic venous disease, may benefit from additional screening for comorbidities. Further studies are needed to clarify the nature of association among comorbidities and chronic venous disease.
© The Author(s) 2014.

Entities:  

Keywords:  anatomic and pathophysiologic classification; chronic venous disease; clinical; comorbidity; etiologic

Mesh:

Year:  2014        PMID: 25005764     DOI: 10.1177/0003319714541988

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  2 in total

1.  The prevalence of poor sleep quality and its association with the risk of obstructive sleep apnea and restless legs syndrome in diabetic patients treated with cyanoacrylate glue for varicose veins.

Authors:  Hüseyin Demirtaş; İlknur Dolu
Journal:  Sleep Breath       Date:  2022-07-01       Impact factor: 2.816

2.  Correlation of obesity & comorbid conditions with chronic venous insufficiency: Results of a single-centre study.

Authors:  Sandeep Mahapatra; Pinjala Ramakrishna; Bhumika Gupta; Arumalla Anusha; Muneer Ahmad Para
Journal:  Indian J Med Res       Date:  2018-05       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.